Turgut KAÇAN, Ebru AKKAŞ ATASEVER, Eda ERDİŞ, Yıllar OKUR, Mehmet Fuat EREN, Birsen YÜCEL, Nalan BABACAN, Saadettin KILIÇKAP

Beyin tümörlü hastaların radyoterapi sonrası retrospektif değerlendirilmesi

Amaç. Bu çalışmada, adjuvan radyoterapi veya kemoradyoterapi ile tedavi edilen beyin tümörlühastaların sağkalım analizi, tedavi yan etkileri ve sağkalımı etkileyen prognostik faktörlerinincelemesi amaçlandı. Yöntem. Çalışmada Cumhuriyet Üniversitesi Tıp Fakültesi Araştırma veUygulama Hastanesi Onkoloji Merkezinde takip edilen 76 beyin tümörlü hasta verileri retrospektifolarak incelendi. Bulgular. Elli bir (%67) erkek, 25 (%33) kadın toplam 76 hasta çalışmaya dahiledildi. Histopatolojik olarak: 18'inde (%24) düşük gradeli glial tümör, 17'sinde (%22) yüksekgradeli glial tümör, 33'ünde (%44) glioblastoma multiforme, 4'ünde (%5) hipofiz adenomu ve4'ünde (%5) medullablastom bulunmaktaydı. Ortanca takip süresi 16 ay (1-199 ay) idi. İki yıllıkgenel sağkalım ve 2 yıllık hastalıksız sağkalım: düşük gradeli glial tümörlerde sırasıyla %83 ve%83, yüksek gradeli glial tümörlerde %46 ve %40, glioblastoma multiforme hastalarında %28 ve%24 olarak tespit edildi. Tek değişkenli analizde hastaların genel sağkalımını, histopatoloji(50, p10, p: 0,016), EasternCooperative Oncology Group performans durumu (p:0,006) ve cerrahi (biopsi ile total rezeksiyonkarşılaştırıldığında p:0,017) etkiledi. Çok değişkenli analizde ise grade (p: 0,013), yaş (p:0,025) veEastern Cooperative Oncology Group performans durumu (p

Patients with brain tumors were evaluated retrospectively af ter radiotherapy

Aim: The purpose of this study is to review survival analysis, side effects and prognostic factors inpatients with brain tumors who were treated with adjuvant radiotherapy or chemoradiotherapy.Methods. In this study, we retrospectively evaluated data of 76 patients with brain tumorsfollowed-up at Cumhuriyet University Medical Faculty of Oncology Centre. Results. This studyanalysed data belonging to 76 patients; 51 (67%) men, and 25 (33%) women. There werehistopathologicly low-grade gliomas in 18 (%24) patients, high-grade gliomas in 17 (%22)patients, glioblastoma multiforme in 33 (%44), pituitary adenomas in 4 (%5) patients andmedullablastoma in 4 (%5) patients. The median follow-up was 16 months (range, 1-199). The 2- year overall and disease-free survival were 83% and 83% at low-grade gliomas, 46% and 40% athigh-grade gliomas, 28% ve 24% at glioblastoma multiforme, respectively. The factors thatdetermined survival were histopathology (p50, p10, p: 0,016), Eastern Cooperative Oncology Group performance status (p:0,006) and surgery (biopsy vs total resection p: 0,017). Eastern Cooperative Oncology Groupperformance status (p

PDF

___

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ. Cancer statistics, 2005. CA Cancer J Clin 2005; 55: 10-30.
2. Shaw EG, Debinski W, Robbins ME. Central nervous system tumors. Gunderson LL, Tepper JE (ed.) Clinical Radiation Oncology (2th.). Elsevier, Philadelphia 2007; 2: 459-91.
3. Davis FG, Freels S, Grutsch J, Barlas S, Brem S. Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973-1991. J Neurosurg 1998; 88: 1-10.
4. Siker ML, Donahue BR, Vogelbaum MA, Tome WA, GilbertMR, Mehta MP. Primary Intracranial Neoplasms. Halperin EC, Perez CA, Brady LW (ed.). Principles and Practice of Radiation Oncology (5th). Lippincott Williams & Wilkins, Philadelphia 2008: 32: 717-49.
5. Davis FG, McCarthy BJ, Freels S, Kupelian V, Bondy ML. The conditional probability of survival of patients with primary malignant brain tumors: surveillance, epidemiology, and end results (SEER) data. Cancer 1999; 85: 485- 91.
6. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352: 997-1003.
7. Central Brain Tumor Registry of the United States. Statistical Report: Primary Brain Tumors in the United States, 1998-2002. Hinsdale, IL: CBTRUS; 2005. Available at: http://www.cbtrus.org/reports/reports.html (Erişim tarihi: 03.09.2012)
8. Curran WJ Jr, Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, Chang CH, Rotman M, Asbell SO, Krisch RE, Nelson DF.. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 1993; 85: 704-10.
9. Coons SW, Johnson PC, Pearl DK. The prognostic significance of Ki-67 labeling indices for oligodendrogliomas. Neurosurgery 1997; 41: 878-85.
10. McGuire CS, Sainani KL, Fisher PG. Both Location and Age Predict Survival in Ependymoma: A SEER Study. Pediatr Blood Cancer 2009; 52: 65-9.
11. Karim AB, Maat B, Hatlevoll R, Menten J, Rutten EH, Thomas DG, Mascarenhas F, Horiot JC, Parvinen LM, van Reijn M, Jager JJ, Fabrini MG, van Alphen AM, Hamers HP, Gaspar L, Noordman E, Pierart M, van Glabbeke M. A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. Int J Radiat Oncol Biol Phys 1996; 36: 549-56.
12. Macdonald DR. Low-grade gliomas, mixed gliomas, and oligodendrogliomas. Semin Oncol 1994; 21: 236-48.
13. Bruner JM. Neuropathology of malignant gliomas. Semin Oncol 1994; 21: 126- 38.
14. Bozdoğan N, Erden E, Atasoy P, Tun K, Savaş A. Glial tümörlerde proliferasyon markerlerinin prognostik önemi. Türk Nöroşirürji Dergisi 2000; 10: 11-5.
15. Chang CH, Horton J, Schoenfeld D, Salazer O, Perez-Tamayo R, Kramer S, Weinstein A, Nelson JS, Tsukada Y. Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study. Cancer 1983; 52: 997-1007.
16. Hulshof MC, Schimmel EC, Andries Bosch D, González González D. Hypofractionation in glioblastoma multiforme. Radiother Oncol 2000; 54: 143-8.
17. Karamitopoulou E, Perentes E, Diamantis I, Maraziotis T. Ki-67 immunoreactivity in human central nervous system tumors: a study with MIB 1 monoclonal antibody on archival material. Acta Neuropathol 1994; 87: 47-54.
18. Kılıçoğlu MK, Tolunay Ş, Ferik Z, Elezoğlu B, Aşık N, Korfalı E, Bekar A, Kocaeli H, Taşkapılıoğlu Ö. Epandimomlarda Ki-67 ekspresyonunun histopatolojik parametreler ile ilişkisi. Uludağ Üniversitesi Tıp Fakültesi Dergisi 2011; 37: 93-7.
19. Burger PC, Scheithauer BW, Vogel FS. Surgical pathology of the nervous system and its coverings. 4th edition. Philadelphia: Churchill Livingstone; 2002; 241-54.
20. Simpson JR, Horton J, Scott C, Curran WJ, Rubin P, Fischbach J, Isaacson S, Rotman M, Asbell SO, Nelson JS, Weinstein AS, Nelson DF. Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: Results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int J Radiat Oncol Biol Phys 1993; 26: 239-44.
21. Pignatti F, van den Bent M, Curran D, Debruyne C, Sylvester R, Therasse P, Afra D, Cornu P, Bolla M, Vecht C, Karim AB; European Organization for Research and Treatment of Cancer Brain Tumor Cooperative Group; European Organization for Research and Treatment of Cancer Radiotherapy Cooperative Group. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol 2002; 20: 2076-84.
22. Safdari H, Fuentes JM, Dubois JB, Alirezai M, Castan P, Vlahovitch B. Radiation necrosis of the brain: Time of onset and incidence related to total dose and fractionation of radiation. Neuroradiology 1985; 27: 44-7.
23. Kumar AJ, Leeds NE, Fuller GN, Van Tassel P, Maor MH, Sawaya RE, Levin VA. Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment. Radiology 2000; 217: 377-84.